Abstract: The present disclosure concerns biologically active materials, particularly materials that comprise a biodegradeable polymer linked to a biologically active agent. The disclosure further concerns materials known as polymer-drug conjugates that typically contain a therapeutic agent, for instance a bioactive cytotoxic drug linked to a polymer backbone. The linkage typically is a convalent linkage. However, in some embodiments the disclosure concerns other polymer conjugates including those where the biologically active agent is an imaging agent, such as a tyrosinamide, a diagnostic agent, or a targeting agent, such as biotin.
Type:
Grant
Filed:
July 30, 2002
Date of Patent:
November 16, 2004
Assignee:
ML Laboratories PLC
Inventors:
Ruth Duncan, Dale Hreczuk-Hirst, Lisa German
Abstract: There is described a method of treatment of a patient requiring analgesia which comprises the separate, simultaneous or sequential administration of a therapeutically effective amount of an opioid analgesic, devazepide and a surfactant.
There is also described a monophasic pharmaceutical composition comprising an amount of devazepide effective in the enhancement of opioid analgesia and a pharmaceutically acceptable surfactant.
Abstract: The invention relates to the inhibitory effects of dextrin sulphate on angiogenesis and in particular the treatment of diseases or disorders which would benefit from the administration of dextrin sulphate.
Abstract: The invention herein described relates to the delivery of therapeutic agents and in particular genetic material, to an animal in combination with dextrin.
Abstract: A polymer-drug conjugate, in which the polymer is the polysaccharide dextrin, linked directly or indirectly to the drug, is effective to deliver the drug to a target site and is biodegradable. The conjugate may be prepared by succinoylating dextrin followed by reaction with the drug or a derivative thereof.
Type:
Grant
Filed:
March 23, 2000
Date of Patent:
January 15, 2002
Assignee:
ML Laboratories
Inventors:
Ruth Duncan, James Cassidy, Lisa German, Dale Hirst
Abstract: The invention provides an agent against HIV and/or related viruses, comprising CD4 or a CD4-like substance and an H2 histone or an H2 histone-like protein. The content of the CD4 or CD4-like substance is preferably less than the antivirally effective dose of that substance alone. The invention also provides an H2 histone or an H2-like protein, for use in a method of medical treatment, in particular against HIV and/or related viruses, and also for use in the manufacture of a pharmaceutical composition against HIV and/or related viruses.
Type:
Grant
Filed:
December 30, 1994
Date of Patent:
February 3, 1998
Assignee:
ML Laboratories
Inventors:
Donald Selwyn Davies, Sunil Shaunak, Nigel John Gooderham, Robert John Edwards
Abstract: The invention provides an agent against HIV-1 and related viruses, the agent being or including dextrin sulphate containing at most two sulphate groups per glucose unit. The invention also provides a composition containing such an agent, and the use of the agent or composition against HIV-1 and related viruses. By restricting the degree of substitution of the dextrin sulphate to a maximum of 2, the invention makes it possible to produce a dextrin sulphate having adequate anti-HIV activity while maintaining toxicity within acceptable limits.